These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 26648749)

  • 61. Optimizing pharmacologic management of inflammatory bowel disease.
    Chang S; Hanauer S
    Expert Rev Clin Pharmacol; 2017 Jun; 10(6):595-607. PubMed ID: 28475384
    [TBL] [Abstract][Full Text] [Related]  

  • 62. When to Start Immunomodulators in Inflammatory Bowel Disease?
    Sharara AI
    Dig Dis; 2016; 34(1-2):125-31. PubMed ID: 26982809
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials.
    Cholapranee A; Hazlewood GS; Kaplan GG; Peyrin-Biroulet L; Ananthakrishnan AN
    Aliment Pharmacol Ther; 2017 May; 45(10):1291-1302. PubMed ID: 28326566
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab.
    Taxonera C; Estellés J; Fernández-Blanco I; Merino O; Marín-Jiménez I; Barreiro-de Acosta M; Saro C; García-Sánchez V; Gento E; Bastida G; Gisbert JP; Vera I; Martinez-Montiel P; Garcia-Morán S; Sánchez MC; Mendoza JL
    Aliment Pharmacol Ther; 2011 Feb; 33(3):340-8. PubMed ID: 21133961
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Anti-tumour necrosis factor therapy for ulcerative colitis: evidence to date.
    Thukral C; Cheifetz A; Peppercorn MA
    Drugs; 2006; 66(16):2059-65. PubMed ID: 17112300
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Pros and cons of medical management of ulcerative colitis.
    Navaneethan U; Shen B
    Clin Colon Rectal Surg; 2010 Dec; 23(4):227-38. PubMed ID: 22131893
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Hibi T; Rutgeerts P;
    Gastroenterology; 2014 Jan; 146(1):85-95; quiz e14-5. PubMed ID: 23735746
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis.
    Berends SE; Strik AS; Löwenberg M; D'Haens GR; Mathôt RAA
    Clin Pharmacokinet; 2019 Jan; 58(1):15-37. PubMed ID: 29752633
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Real-World Long-Term Remission Maintenance for 10 Years With Thiopurines in Ulcerative Colitis.
    Matsumoto S; Mashima H
    Crohns Colitis 360; 2021 Jan; 3(1):otab003. PubMed ID: 36777065
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Intravenous corticosteroids in moderately active ulcerative colitis refractory to oral corticosteroids.
    Llaó J; Naves JE; Ruiz-Cerulla A; Marín L; Mañosa M; Rodríguez-Alonso L; Cabré E; Garcia-Planella E; Guardiola J; Domènech E
    J Crohns Colitis; 2014 Nov; 8(11):1523-8. PubMed ID: 25066954
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Infliximab for hospitalized patients with severe ulcerative colitis.
    Regueiro M; Curtis J; Plevy S
    J Clin Gastroenterol; 2006 Jul; 40(6):476-81. PubMed ID: 16825928
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Treatment of ulcerative colitis.
    Blonski W; Buchner AM; Lichtenstein GR
    Curr Opin Gastroenterol; 2014 Jan; 30(1):84-96. PubMed ID: 24285003
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation.
    Taxonera C; Iglesias E; Muñoz F; Calvo M; Barreiro-de Acosta M; Busquets D; Calvet X; Rodríguez A; Pajares R; Gisbert JP; López-Serrano P; Pérez-Calle JL; Ponferrada Á; De la Coba C; Bermejo F; Chaparro M; Olivares D; Alba C; Fernández-Blanco I
    Dig Dis Sci; 2017 Feb; 62(2):481-490. PubMed ID: 27995400
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Indirect comparison of vedolizumab and adalimumab for biologic-naive patients with ulcerative colitis.
    Dignass AU; Siegmund B; Goertz R; Schneidewind G; Fanter L
    Scand J Gastroenterol; 2019 Feb; 54(2):178-187. PubMed ID: 30735443
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review.
    Damião AOMC; de Azevedo MFC; Carlos AS; Wada MY; Silva TVM; Feitosa FC
    World J Gastroenterol; 2019 Mar; 25(9):1142-1157. PubMed ID: 30863001
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination With Vedolizumab in Patients With Refractory Ulcerative Colitis.
    Pellet G; Stefanescu C; Carbonnel F; Peyrin-Biroulet L; Roblin X; Allimant C; Nachury M; Nancey S; Filippi J; Altwegg R; Brixi H; Fotsing G; de Rosamel L; Shili S; Laharie D;
    Clin Gastroenterol Hepatol; 2019 Feb; 17(3):494-501. PubMed ID: 30213584
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Update on the management of ulcerative colitis.
    Taba Taba Vakili S; Taher M; Ebrahimi Daryani N
    Acta Med Iran; 2012; 50(6):363-72. PubMed ID: 22837114
    [TBL] [Abstract][Full Text] [Related]  

  • 78. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2.
    Sandborn WJ; Colombel JF; D'Haens G; Van Assche G; Wolf D; Kron M; Lazar A; Robinson AM; Yang M; Chao JD; Thakkar R
    Aliment Pharmacol Ther; 2013 Jan; 37(2):204-13. PubMed ID: 23173821
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis.
    Danese S; Fiorino G; Peyrin-Biroulet L; Lucenteforte E; Virgili G; Moja L; Bonovas S
    Ann Intern Med; 2014 May; 160(10):704-11. PubMed ID: 24842416
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Tacrolimus therapy as an alternative to thiopurines for maintaining remission in patients with refractory ulcerative colitis.
    Yamamoto S; Nakase H; Matsuura M; Masuda S; Inui K; Chiba T
    J Clin Gastroenterol; 2011 Jul; 45(6):526-30. PubMed ID: 21336140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.